Mirabegron

Mirabegron (formerly YM-178, trade name Myrbetriq, Betmiga in Spain) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.

Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.

Mirabegron uses a CGI red sphere with a face, arms, and legs, intended to resemble a bladder.

Medical uses

Its primary use is in the treatment of overactive bladder. Mirabegron has also recently been shown to activate brown fat and increase metabolism. In a small study of 15 healthy, lean men, Mirabegron was shown to increase basal heart rate, metabolic rate and blood pressure which are signs of cardiovascular stimulation.

Adverse effects

Adverse effects by incidence:

Very common (>10% incidence) adverse effects include:

• Elevated blood pressure

Common (1-10% incidence) adverse effects include:

• Xerostomia (dry mouth)
• Nasopharyngitis
• Urinary tract infection (UTI)
• Headache
• Influenza
• Constipation
• Dizziness
• Arthralgia
• Cystitis
• Back pain
• Upper respiratory tract infection (URTI)
• Sinusitis
• Diarrhoea
• Tachycardia (high heart rate)
• Fatigue
• Abdominal pain
• Neoplasms (cancers)

Rare (<1% incidence) adverse effects include:

• Palpitations
• Blurred vision
• Glaucoma
• Dyspepsia (indigestion)
• Gastritis
• Abdominal distension
• Rhinitis
• Elevations in liver enzymes (GGT, AST, ALT & LDH)
• Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
• Reproductive system disorders (e.g., vulvovaginal pruritis, vaginal infection)
• Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)
• Stevens-Johnson syndrome associated with increased serum ALT, AST and bilirubin
• Urinary retention

References

External links

• Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology 4 (6): 315â€"24. doi:10.1177/1756287212457114. PMC 3491758. PMID 23205058.